Open an account

Dogwood Therapeutics

DWTX · NASDAQ

$1.15−$0.06 (−4.96%)TodayMarket closed ·
Prev close $1.21

DWTX analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 4 analysts

Average $13.77 (+1097.4% upside)

Low
$12.12
Now
$1.15
High
$15.75

Upgrades and downgrades

The latest rating actions, newest first

DWTX analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.May 19, 2026MaintainsBuy
HC Wainwright & Co.Apr 27, 2026MaintainsBuy
HC Wainwright & Co.Feb 20, 2026MaintainsBuy
HC Wainwright & Co.Jan 30, 2026MaintainsBuy

The case for and against

Updated Oct 14, 2026

Bull case

Dogwood Therapeutics is viewed positively because Halneuron’s upcoming Phase 2b topline results in September could validate a first-in-class NaV1.7 inhibitor for chemotherapy induced neuropathic pain, a setting with no drugs specifically approved in the U.S. and clear unmet need. The long-term extension should add valuable repeat-dosing safety and durability data, helping define Phase 3 design and commercial dosing intervals, which could materially improve the market’s view of Halneuron’s addressable opportunity. Separately, the April 23 licensing of IMC-1 and IMC-2 to PridCor shifts development funding and execution risk away from Dogwood while preserving up to $100M in milestones and tiered royalties of up to 15%.

Bear case

Dogwood Therapeutics is a pre-revenue, development-stage biopharmaceutical company whose valuation depends almost entirely on a speculative pipeline and expected revenues through 2033, leaving the stock highly exposed to execution risk rather than current operating strength. The company’s own risk framework highlights multiple material uncertainties—clinical, regulatory, commercial, collaboration, financial, and intellectual property—that could derail development and limit the probability of meaningful value creation. Although the analysis cites an rNPV of $374M and pro forma net cash of $17.9M, the absence of revenue and reliance on a risk-adjusted model underscore a fragile fundamental profile and support a negative outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.